Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...

Marleen I. Meyers, MD, emphasizes prioritizing whole foods, particularly fruits and vegetables, over relying on supplements for patients with cancer.

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...